Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
Experiment 1
Curated date: 2021/12/02
Curator: Mmarin
Revision editor(s): WikiWorks, LGeistlinger, Mmarin, Peace Sandy, Folakunmi
Subjects
- Location of subjects
- Russian Federation
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Antimicrobial agent antibiotic,antibiotics,Antibiotika,Antibiotikum,antibiotique,antimicrobial,antimicrobial agents,microbicide,microbicides,Antimicrobial agent,antimicrobial agent
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- azithromycin-lactulose treated (day 0)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- azithromycin-lactulose treated (day 18)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- administered a single daily dosage of 10 mg/kg body weight azithromycin in addition with 20 mg/kg body weight lactulose per day, as powder for oral suspension.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 42
- Group 1 sample size Number of subjects in the case (exposed) group
- 42
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V3-V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- Mann-Whitney (Wilcoxon)
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
Signature 1
Source: Table 1
Description: AZ azithromycin. A and L represent higher mean relative abundance for the azithromycin only and azitrhomycin + lactulose groups, respectively Arrows point up or down indicate an increase or increase compared to the relative abundance at day 0, respectively
Abundance in Group 1: decreased abundance in azithromycin-lactulose treated (day 18)
| NCBI | Quality Control | Links |
|---|---|---|
| Enterobacter | ||
| Prevotella |
Revision editor(s): Mmarin
Signature 2
Source: Table 1
Description: AZ azithromycin. A and L represent higher mean relative abundance for the azithromycin only and azitrhomycin + lactulose groups, respectively Arrows point up or down indicate an increase or increase compared to the relative abundance at day 0, respectively
Abundance in Group 1: increased abundance in azithromycin-lactulose treated (day 18)
| NCBI | Quality Control | Links |
|---|---|---|
| Anaerostipes | ||
| Enterococcus | ||
| Lactobacillus | ||
| Roseburia | ||
| Ruminococcus |
Revision editor(s): Mmarin
Experiment 2
Curated date: 2021/12/03
Curator: Mmarin
Revision editor(s): WikiWorks, LGeistlinger, Mmarin, Folakunmi
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- azithromycin treated (day 0)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- azithromycin treated (day 18)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- administered 10 mg/kg body weight per day of azithromycin, as powder for oral suspension.
Lab analysis
Statistical Analysis
Signature 1
Source: Table 1
Description: Arrows point up or down indicate an increase or increase compared to the relative abundance at day 0, respectively
Abundance in Group 1: decreased abundance in azithromycin treated (day 18)
| NCBI | Quality Control | Links |
|---|---|---|
| Enterobacter |
Revision editor(s): Mmarin
Signature 2
Source: Table 1
Description: Arrows point up or down indicate an increase or increase compared to the relative abundance at day 0, respectively
Abundance in Group 1: increased abundance in azithromycin treated (day 18)
| NCBI | Quality Control | Links |
|---|---|---|
| Adlercreutzia | ||
| Lachnospira |
Revision editor(s): Mmarin
Experiment 3
Curated date: 2021/12/03
Curator: Mmarin
Revision editor(s): WikiWorks, LGeistlinger, Mmarin, Folakunmi
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- azithromycin treated (day 60)
Lab analysis
Statistical Analysis
Signature 1
Source: Table 1
Description: Arrows point up or down indicate an increase or increase compared to the relative abundance at day 0, respectively
Abundance in Group 1: decreased abundance in azithromycin treated (day 60)
| NCBI | Quality Control | Links |
|---|---|---|
| Enterobacter | ||
| Odoribacter | ||
| Paraprevotella | ||
| Prevotella | ||
| Sutterella |
Revision editor(s): Mmarin
Signature 2
Source: Table 1
Description: Arrows point up or down indicate an increase or increase compared to the relative abundance at day 0, respectively
Abundance in Group 1: increased abundance in azithromycin treated (day 60)
| NCBI | Quality Control | Links |
|---|---|---|
| Adlercreutzia | ||
| Alkaliphilus | ||
| Streptococcus | ||
| Veillonella |
Revision editor(s): Mmarin
Experiment 4
Curated date: 2021/12/03
Curator: Mmarin
Revision editor(s): WikiWorks, LGeistlinger, Mmarin, Folakunmi
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- azithromycin treated (0-18)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- azithromycin-lactulose treated (0-18)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- administered a single daily dosage of 10 mg/kg body weight azithromycin in addition with 20 mg/kg body weight lactulose per day, as powder for oral suspension.
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- increased
- Richness Number of species
- unchanged
Signature 1
Source: Table 1
Description: AZ azithromycin. A and L represent higher mean relative abundance for the azithromycin only and azitrhomycin + lactulose groups, respectively Arrows point up or down indicate an increase or increase compared to the relative abundance at day 0, respectively
(day 18)
Abundance in Group 1: increased abundance in azithromycin-lactulose treated (0-18)
| NCBI | Quality Control | Links |
|---|---|---|
| Anaerostipes |
Signature 2
Source: Table 1
Description: AZ azithromycin. A and L represent higher mean relative abundance for the azithromycin only and azitrhomycin + lactulose groups, respectively Arrows point up or down indicate an increase or increase compared to the relative abundance at day 0, respectively
(day 60)
Abundance in Group 1: increased abundance in azithromycin-lactulose treated (0-18)
| NCBI | Quality Control | Links |
|---|---|---|
| Streptococcus |
Experiment 5
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- azithromycin treated (0-60)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- azithromycin-lactulose treated (0-60)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- patients administered a single daily dosage of 10 mg/kg body weight azithromycin in addition with 20 mg/kg body weight lactulose per day, as powder for oral suspension.
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- increased
- Richness Number of species
- unchanged
Signature 1
Source: Table 1
Description: Significant differences in relative abundance between groups and time points
Abundance in Group 1: increased abundance in azithromycin-lactulose treated (0-60)
| NCBI | Quality Control | Links |
|---|---|---|
| Dysgonomonas |
Revision editor(s): Folakunmi
Signature 2
Source: Table 1
Description: Significant differences in relative abundance between groups and time points
Abundance in Group 1: decreased abundance in azithromycin-lactulose treated (0-60)
| NCBI | Quality Control | Links |
|---|---|---|
| Alkaliphilus | ||
| Streptococcus |
Revision editor(s): Folakunmi
Experiment 6
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- azithromycin treated at day 18
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- azithromycin-lactulose at day 18
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- increased
- Richness Number of species
- unchanged
Signature 1
Source: Table 1
Description: Significant differences in relative abundance between groups at day 18 time point
Abundance in Group 1: increased abundance in azithromycin-lactulose at day 18
| NCBI | Quality Control | Links |
|---|---|---|
| Anaerostipes | ||
| Blautia | ||
| Butyricimonas | ||
| Coprobacillus | ||
| Erysipelothrix | ||
| Megasphaera |
Revision editor(s): Folakunmi
Experiment 7
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- azithromycin treated at day 60
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- azithromycin-lactulose at day 60
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- increased
- Richness Number of species
- unchanged
Signature 1
Source: Table 1
Description: Significant differences in relative abundance between groups at day 20 time point
Abundance in Group 1: increased abundance in azithromycin-lactulose at day 60
| NCBI | Quality Control | Links |
|---|---|---|
| Dysgonomonas |
Revision editor(s): Folakunmi
Signature 2
Source: Table 1
Description: Significant differences in relative abundance between groups at day 20 time point
Abundance in Group 1: decreased abundance in azithromycin-lactulose at day 60
| NCBI | Quality Control | Links |
|---|---|---|
| Alkaliphilus | ||
| Streptococcus |
Revision editor(s): Folakunmi
Experiment 8
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- azithromycin-lactulose treated (day 0)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- azithromycin-lactulose treated (day 60)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- administered a single daily dosage of 10 mg/kg body weight azithromycin in addition with 20 mg/kg body weight lactulose per day, as powder for oral suspension.
